C4 Therapeutics (CCCC) Net Equity Issued and Repurchased (2020 - 2025)

C4 Therapeutics' Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $7.5 million for Q3 2025.

• On a quarterly basis, Net Equity Issued and Repurchased rose 27.32% year-over-year to $7.5 million in Q3 2025; TTM through Sep 2025 was $89.8 million, a 15.61% increase from a year earlier, with the FY2025 full-year figure at $116.9 million, up 484.35% from the prior year.
• Net Equity Issued and Repurchased slipped to $7.5 million in Q3 2025 per CCCC's latest filing, from $82.3 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $82.3 million in Q4 2024 and bottomed at $5.9 million in Q3 2024.
• The 3-year median for Net Equity Issued and Repurchased is $14.1 million (2024), against an average of $33.5 million.
• Across the five-year window, Net Equity Issued and Repurchased jumped 42.63% in 2024 and rose 27.32% in 2025, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $57.7 million in 2023, then soared by 42.63% to $82.3 million in 2024, then sank by 90.86% to $7.5 million in 2025.
• Per Business Quant, the three latest CCCC Net Equity Issued and Repurchased figures stand at $7.5 million (Q3 2025), $82.3 million (Q4 2024), and $5.9 million (Q3 2024).